Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI
Jul 07, 2026
View online
Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI
Prostate Cancer: New ESTRO Recommendations for Precision Radiotherapy
Monica Bertagnolli: Don’t Abolish the NIH, Fix It
TROP2 Emerges as a Therapeutic Target in Colorectal Cancer Cell States Linked to Metastasis and Resistance
Felicia Marie Knaul: WHO to Present First Global Estimates of 5-Year Breast Cancer Survival
Micheál Martin: A Significant Milestone for Irish Research with a €100 Million Investment
Immunotherapy and Summer Sun: What Patients Should Know About Skin Safety, Baths, and Heat
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA
ACOG Foundation 2026 Request for Grant Proposals
25th Annual International Congress on the Future of Breast Cancer West
APPOS Austin 2026
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
